Sirnaomics’ RNAi treatment shows novel mechanism of action for solid tumors

Sino-American RNAi therapeutics company Sirnaomics (2257: HK) today announced the publication of a research article with NAR Cancer.

The article reveals a novel mechanism of action of lead RNAi cancer drug candidate, STP707, a polypeptide nanoparticle (PNP) formulation comprised of two active siRNA (small interfering RNA) inhibitors targeting TGF-β1 and COX-2 for intravenous treatment of solid tumors. The publication provides support to the company’s ongoing clinical studies and a strong rationale for combination treatment with immune-checkpoint inhibitors.

Sirnaomics noted that the published study, ‘Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors’ demonstrates how PNP delivered the siRNA to multiple cell types besides hepatocytes in the liver. It also demonstrates that STP-707 can simultaneously deliver the siRNAs targeting TGF-β1 and COX-2 to tumor cells.